SANOFI-AVENTIS has today
advised of the TGA approval of its
new antiarrhythmic treatment
Multaq (dronedarone) 400mg.
Multaq is indicated to reduce the
risk of cardiovascular
hospitalisation in patients with
paroxysmal or persistent atrial
fibrillation or atrial flutter, with a
recent episode and associated
cardiovascular risk factors, on top
of standard therapy.
The medication has been shown
to reduce the primary endpoint of
cardiovascular hospitalisation or
death from any cause by 24% in a
trial of 4628 patients.The above article was sent to subscribers in Pharmacy Daily's issue from 29 Jul 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Jul 10
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
AUSTRALIA’S public hospitals are facing their lengthiest wait times on record for planned surgeries, with emergency departments struggling under access blockages, according to the latest annual Public Hospital Report Card by the Australian Medical Association (AMA).
THE University of South Australia has released a new study to help healthcare workers better support women with persistent pelvic pain, including symptoms that are suggestive of gynaecological, lower urinary tract, bowel, sexual, and pelvic floor dysfunction.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.